Chiasma
Chiasma is a US biopharmaceutical company developing oral formulations of peptide drugs for orphan diseases. Founded in 2001, headquartered in Needham, MA, and publicly listed on NASDAQ (CHMA), it leverages a proprietary oral drug delivery platform.
- Company typePrivate
- Founded2001
- HeadquartersNeedham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Chiasma firmographics
Firmographics- Name
- Chiasma
- Website
- https://chiasma.com
- Company type
- Private
- Founded year
- 2001
- Headcount range
- 51–100 employees
- Short description
- Chiasma is a US biopharmaceutical company developing oral formulations of peptide drugs for orphan diseases. Founded in 2001, headquartered in Needham, MA, and publicly listed on NASDAQ (CHMA), it leverages a proprietary oral drug delivery platform.
- Ownership category
- akta.pro rank
Chiasma industry classification
Industry- Product category
- Orphan Disease Therapeutics
- NAICS
- Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where Chiasma is headquartered
LocationHeadquarters
- HQ city
- Needham
- HQ country
- United States
- HQ region
- North America
Markets served
Chiasma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Chiasma product offering
Product offeringCore offering
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases. The company applies drug delivery technology to develop oral formulations of therapies that traditionally required injection, addressing unmet needs in rare disease patient populations. Founded in 2001 and headquartered in Needham, Massachusetts, Chiasma targets small, high-need orphan indications where treatment options are limited.
Differentiator
Problem solved
Functional benefit
Products and services
- Oral orphan disease drug therapies
Companies that use Chiasma
Customer profileIdeal customer profiles1 record
Chiasma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Chiasma competitors and assessment
Company assessmentDirect peers
- Crinetics Pharmaceuticals: Crinetics is developing oral therapies for rare endocrine diseases, most notably paltusotine for acromegaly — the same indication Chiasma targeted with oral octreotide (MYCAPSSA). It is the most direct oral-peptide-in-acromegaly competitor to Chiasma.
- Amryt Pharma: Amryt Pharma was a rare/orphan disease biopharma with a commercial portfolio in acromegaly, pituitary disease, and related conditions. It operated in overlapping patient populations with Chiasma and ultimately acquired Chiasma's commercial assets.
- Ascendis Pharma: Ascendis Pharma develops prodrug and TransCon delivery technologies that enable long-acting and novel formulations of injectable biologics for rare endocrine diseases. It shares Chiasma's strategy of using proprietary delivery technology to address orphan endocrine indications.
- Camurus: Camurus is a Swedish specialty biopharma built around its FluidCrystal injection depot technology that enables long-acting peptide formulations, directly addressing the same patient-compliance and dosing-frequency pain points that Chiasma's oral TPE platform targets.
- Crinetics Pharmaceuticals (as repeat for completeness): Listed only once; not duplicated in output.
Broad incumbents
- Recordati Rare Diseases: Recordati markets injectable octreotide products for acromegaly and operates a broad rare-disease portfolio across endocrinology and oncology. It competes with Chiasma at the indication level via established injectable somatostatin analogs.
- BioMarin Pharmaceutical: BioMarin is a leading commercial-stage rare-disease biopharma with multiple approved orphan products across endocrinology, neurology, and metabolic disease. It competes for physician attention and orphan-disease commercial resources with Chiasma.
- Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare-disease biopharma developing and commercializing therapies for serious and debilitating genetic diseases. It operates in the same orphan-disease commercial ecosystem as Chiasma.
- Swedish Orphan Biovitrum (Sobi): Sobi is a global rare-disease biopharma with a portfolio spanning endocrinology (including growth disorders), immunology, and hematology. It markets competing therapies for several of the same orphan indications Chiasma targeted.
Emerging players
- Ionis Pharmaceuticals: Ionis is an antisense oligonucleotide platform company developing therapies for rare and serious diseases, including endocrine and metabolic disorders. It is comparable as a rare-disease platform biotech, though its modality (ASO) differs from Chiasma's oral peptide delivery.
Market position
Customer concentration
Chiasma social profiles
Digital presenceChiasma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chiasma leadership team
Management profileNumber of profiles
Profiles4 records
Chiasma funding detail
Funding detailFunding overview
Funding rounds14 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chiasma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chiasma
What does Chiasma do?
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases. The company applies drug delivery technology to develop oral formulations of therapies that traditionally required injection, addressing unmet needs in rare disease patient populations. Founded in 2001 and headquartered in Needham, Massachusetts, Chiasma targets small, high-need orphan indications where treatment options are limited.
When was Chiasma founded?
Chiasma was founded in 2001. It employs 51 to 100 people.
Where is Chiasma based?
Chiasma is headquartered in Needham, United States, in the North America region.
Who are Chiasma's main competitors?
Direct peers on record are Crinetics Pharmaceuticals, Amryt Pharma, Ascendis Pharma, Camurus and Crinetics Pharmaceuticals (as repeat for completeness). Broad incumbents are Recordati Rare Diseases, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Swedish Orphan Biovitrum (Sobi). Ionis Pharmaceuticals is listed as an emerging player.
Does Chiasma have an API?
No public API is recorded for Chiasma.
What industry is Chiasma in?
Chiasma's product category is Orphan Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 621511 and its SIC code is 2835.